Research Progress of Rheumatic Immune Diseases

Dear Colleagues,

Rheumatology is a constantly evolving discipline. The prognosis of many rheumatologic diseases has greatly improved as a result of substantial progress in disease management, even though their pathogenetic aspects, both genetic and environmental, remain unresolved. The application of molecular and cellular profiling techniques revealed marked heterogeneity of the pathomechanisms of some diseases, particularly rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), contributing to the variation of their clinical phenotype and treatment response. Ongoing efforts to dissect this marked disease heterogeneity in RA and in SLE represent a challenge for the future development of precision medicine and therapeutic target validation approaches in these diseases. Unfortunately, the new treatments do not appear to decrease the incidence of some potentially life-threatening complications, such as macrophage activation syndrome and interstitial lung diseases in systemic-onset juvenile idiopathic arthritis/still disease. Therefore, the understanding of immune dysregulation underlying these pathologies is relevant to identifying biomarkers for their early identification. However, the risk/benefit profile of the new therapeutic agents in real-world rheumatology practice deserves further investigation and surveillance. Autoinflammatory disorders (inflammasomopathies and interferonopathies), at the crossroads between immunology and rheumatology, can masquerade as rheumatologic diseases; therefore, the knowledge of their extremely heterogeneous presentation, molecular diagnostic approach, and promising targeted treatment encompasses the rheumatologic expertise.

The present topic aims to collect original contributions that represent novel insights into rheumatologic/autoinflammatory disease pathology and clinical treatment of both adults and children, in order to offer the scientific community knowledge and actionable suggestions for clinical practice.

Prof. Dr. Rita Consolini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• systemic lupus erythematosus
• rheumatologic diseases
• rheumatoid arthritis
• autoinflammatory diseases
• inflam-masomopathies
• interferonopathies